Publications by authors named "Dominic Muston"

Claim this Profile
C
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.
Bradley J Monk, Sophie van Mens, Oliver Hale, Jennifer Boer, Frank van Hees, Dominic Muston

Oncol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit.
Dominic Muston

Appl Health Econ Health Policy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer.
Neeharika Agnihotri, Apoorva Ambavane, Lin Fan, Weiyan Li, HyunKyoo Yoo, Dominic Muston

Pancreatology· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
David Elsea, Dominic Muston, Lin Fan, Adela Mihai, Yang Meng

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons, Dominic Muston

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons, Dominic Muston

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
Lin Fan, Yuanyuan Zhang, Peter Maguire, Dominic Muston, Matthew Monberg

J Mark Access Health Policy· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Rachel Evans, Neil Hawkins, Pascale Dequen-O'Byrne, Charles McCrea, Dominic Muston

Target Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Wei Gao, Dominic Muston, Matthew Monberg, Kimmie McLaurin, Robert Hettle

Pharmacoeconomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Dominic Muston, Robert Hettle, Matthew Monberg, Kimmie K McLaurin, Wei Gao

Gynecol Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).
Jana Stefanickova, Jose Cunha-Vaz, Michael Ulbig, Ian Pearce, Alvaro Fernández-Vega Sanz, Dominic Muston

Acta Ophthalmol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data.
Dominic Muston, Jean-Francois Korobelnik, Tim Reason, Neil Hawkins, Ismini Chatzitheofilou

BMC Ophthalmol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies.
John Brazier, Dominic Muston, Henrietta Konwea, G Sarah Power, Victor Barzey

Invest Ophthalmol Vis Sci· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
Luke Bamber, Dominic Muston, Euan McLeod, Anne Guillermin, Julia Lowin

Thromb J· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME).
Jean-Francois Korobelnik, Jos Kleijnen, Shona H Lang, Richard Birnie, Regina M Leadley, Dominic Muston

BMC Ophthalmol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.
Justyna M Starczewska Amelio, Javier Cid Ruzafa, Kamal Desai, Spiros Tzivelekis, Dominic Muston

BMC Cancer· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
David Lee, Dominic Muston, Alison Sweet, Chris Cunningham, Andrew Slater

Appl Health Econ Health Policy· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic evaluation of topical treatments for actinic keratosis.
Dominic Muston, Anthony Downs, Vincent Rives

J Dermatolog Treat· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
Christopher R Chapple, Vik Khullar, Zahava Gabriel, Dominic Muston, Caty Ebel Bitoun

Eur Urol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis